Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The Altitude Inflammatory Bowel Disease Study

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
Statusas
Rėmėjai
University of Zurich
Bendradarbiai
Triemli Hospital
Zurich Center for Integrative Human Physiology
Institute of Biostatistics
University Hospital Inselspital, Berne
Institute of Physiology Irchel
Institute of Veterinary Physiology
Swiss Aeromedical Center Switzerland
Institute of Experimental Immunology
Institute of Pathology, University Hospital Zurich

Raktažodžiai

Santrauka

This is a prospective, controlled and observational study. Participants underwent a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Clinical parameters, as well as blood and stool samples and biopsies from the sigmoid colon (by sigmoidoscopy) are collected at subsequent time points. The investigators goal is to evaluate if a 3-hour stay at high altitude (4, 000 m) can alter disease activity and can modulate a pro inflammatory reaction.

apibūdinimas

To evaluate the potential influence of hypoxia on the course of IBD on a biomolecular level, and to test the effects of hypoxia under standardized conditions, the investigators initiated a prospective and controlled investigation in healthy controls and IBD patients in stable remission. the investigators primary aim is to show that a 3-hour stay at high altitude can alter disease activity of IBD. Ten healthy volunteers, 11 Crohn's disease (CD) patients and 9 ulcerative colitis (UC) patients underwent a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l. in a hypobaric low-pressure chamber situated at the Swiss Aeromedical Center, Dubendorf, Switzerland. Stool samples for the analysis of calprotectin and microbiotal composition, biopsy samples from the rectosigmoid region, and blood samples were repetitively collected and analysed in conjunction with detailed records of clinical symptoms over a subsequent interval of 4 weeks.

Datos

Paskutinį kartą patikrinta: 06/30/2016
Pirmasis pateikimas: 07/11/2016
Numatytas registravimas pateiktas: 07/25/2016
Pirmas paskelbtas: 07/28/2016
Paskutinis atnaujinimas pateiktas: 07/25/2016
Paskutinis atnaujinimas paskelbtas: 07/28/2016
Faktinė studijų pradžios data: 04/30/2014
Numatoma pirminio užbaigimo data: 08/31/2015
Numatoma studijų užbaigimo data: 11/30/2016

Būklė ar liga

Inflammatory Bowel Disease

Intervencija / gydymas

Other: hypobaric pressure chamber

Other: hypobaric pressure chamber

Fazė

-

Rankų grupės

RankaIntervencija / gydymas
Other: hypobaric pressure chamber
The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
Other: hypobaric pressure chamber
hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysAll
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- had a diagnosis of Crohn's disease or ulcerative colitis at least 6 months prior to inclusion

- gave written consent

- were in clinical remission (measured by Harvey Bradshaw Activity Index (HBI) in CD and the partial Mayo Score for UC)

Exclusion Criteria:

- had contraindications for a sigmoidoscopy

- had intercurrent bacterial or viral intestinal disease (by culture or serology)

- were pregnant or breast feeding

- had a severe concomitant disease which excluded from participating in the study by means of the study physician

- were likely to or showed no cooperation for the study procedures

- had active infection or systemic antibiotic, antiviral or antifungal treatment 3 weeks before baseline

- were suffering from short-bowel syndrome

- were receiving parenteral nutrition

- had a clinical condition which did not allow a stay at heights of 4,000 m.a.s.l.

- were claustrophobic

Rezultatas

Pirminės rezultatų priemonės

1. Change of Harvey Bradshaw Activity Index (HBI) [4 weeks]

Harvey Bradshaw Activity Index (HBI) in Crohn's disease (CD): To calculate the clinical activity of patients with CD the Harvey Bradshaw Activity Index (HBI) was used. This index includes general wellbeing, abdominal pain, the number of bowel movements, abdominal resistance and CD associated extraintestinal diseases. Each category has a point value assigned and from the sum of all categories a point value is calculated.

2. Change of partial Mayo Score [4 weeks]

partial Mayo Score for Ulcerative Colitis (UC): To calculate the clinical activity of patients with UC the partial Mayo Score was used. This clinical index includes the stool frequency, the amount of blood in the stool and the physician rating of disease activity. Each category has a point value assigned from 0 to 3 and from the sum of all categories a point value was calculated. Remission is defined as 0-1 points, mild disease 2-4 points, moderate disease 5-6 points and severe disease as 7-9 points.

Antrinės rezultatų priemonės

1. change in levels of hypoxia-inducible factor (HIF)-1 [4 weeks]

2. Change in bladder volume [4 weeks]

measured by sonography (ml)

3. Change in levels of angiotensin and vasopressin in urine [4 weeks]

4. Change in levels of catecholamines (adrenaline and noradrenaline) in blood [4 weeks]

5. Change in pro- and anti-inflammatory cytokins [4 weeks]

tumor necrosis factor alpha (TNF-α), tumor necrosis factor (TNF), interleukin-1β (IL-1β), interferon-gamma (IFNg), interleukin-10 (IL-10)

6. Inflammation in sigmoid colon [4 weeks]

Assessed by sigmoidoscopy: signs of inflammation: decreased vascular pattern ulcers bleeding

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge